期刊
TRANSFUSION
卷 61, 期 9, 页码 2658-2667出版社
WILEY
DOI: 10.1111/trf.16580
关键词
convalescent plasma; COVID-19; SARS-CoV-2; serology
类别
资金
- Center for Strategic Scientific Initiatives, National Cancer Institute [CA091842]
- National Center for Advancing Translational Sciences [UL1TR002345]
- National Institute of Diabetes and Digestive and Kidney Diseases [RO1DK111930]
This study aimed to establish correlations and analogous cutoffs between different serological assays, finding relationships between various assays and determining the best correlative index for establishing high-titer units. The results help reconcile the large body of serological data generated during the COVID-19 pandemic, providing insights into the relationships between different assays and their ability to distinguish high-titer specimens.
Background The COVID-19 pandemic has been accompanied by the largest mobilization of therapeutic convalescent plasma (CCP) in over a century. Initial identification of high titer units was based on dose-response data using the Ortho VITROS IgG assay. The proliferation of severe acute respiratory syndrome coronavirus 2 serological assays and non-uniform application has led to uncertainty about their interrelationships. The purpose of this study was to establish correlations and analogous cutoffs between multiple serological assays. Methods We compared the Ortho, Abbott, Roche, an anti-spike (S) ELISA, and a virus neutralization assay. Relationships relative to FDA-approved cutoffs under the CCP emergency use authorization were identified in convalescent plasma from a cohort of 79 donors from April 2020. Results Relative to the neutralization assay, the spearman r value of the Ortho Clinical, Abbott, Roche, anti-S ELISA assays was 0.65, 0.59, 0.45, and 0.76, respectively. The best correlative index for establishing high-titer units was 3.87 signal-to-cutoff (S/C) for the Abbott, 13.82 cutoff index for the Roche, 1:1412 for the anti-S ELISA, 1:219 by the neutralization assay, and 15.9 S/C by the Ortho Clinical assay. The overall agreement using derived cutoffs compared to a neutralizing titer of 1:250 was 78.5% for Abbott, 74.7% for Roche, 83.5% for the anti-S ELISA, and 78.5% for Ortho Clinical. DISCUSSION Assays based on antibodies against the nucleoprotein were positively associated with neutralizing titers and the Ortho assay, although their ability to distinguish FDA high-titer specimens was imperfect. The resulting relationships help reconcile results from the large body of serological data generated during the COVID-19 pandemic.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据